RNAmut: Robust identification of somatic mutations in acute myeloid leukemia using RNA-sequencing

Muxin Gu; Maximillian Zwiebel; Swee Hoe Ong; Nick Boughton; Josep Nomdedeu; Faisal Basheer; Yasuhito Nannya; Pedro M. Quiros; Seishi Ogawa; Mario Cazzola; Roland Rad; Adam P. Butler; M. S. Vijayabaskar; George S. Vassiliou

doi:10.3324/haematol.2019.230821

RNAmut: Robust identification of somatic mutations in acute myeloid leukemia using RNA-sequencing

Muxin Gu, Maximillian Zwiebel, Swee Hoe Ong, Nick Boughton, Josep Nomdedeu, Faisal Basheer, Yasuhito Nannya, Pedro M. Quiros, Seishi Ogawa, Mario Cazzola, Roland Rad, Adam P. Butler, M. S. Vijayabaskar, George S. Vassiliou

Research output: Contribution to journal › Letter › peer-review

16 Scopus citations

Original language	English
Pages (from-to)	E290-E293
Journal	Haematologica
Volume	105
Issue number	6
DOIs	https://doi.org/10.3324/haematol.2019.230821
State	Published - 1 Jun 2020
Externally published	Yes

Access to Document

10.3324/haematol.2019.230821

Cite this

Gu, M., Zwiebel, M., Ong, S. H., Boughton, N., Nomdedeu, J., Basheer, F., Nannya, Y., Quiros, P. M., Ogawa, S., Cazzola, M., Rad, R., Butler, A. P., Vijayabaskar, M. S., & Vassiliou, G. S. (2020). RNAmut: Robust identification of somatic mutations in acute myeloid leukemia using RNA-sequencing. Haematologica, 105(6), E290-E293. https://doi.org/10.3324/haematol.2019.230821

@article{8339f4eca66a4955a09681282cf5d562,

title = "RNAmut: Robust identification of somatic mutations in acute myeloid leukemia using RNA-sequencing",

author = "Muxin Gu and Maximillian Zwiebel and Ong, {Swee Hoe} and Nick Boughton and Josep Nomdedeu and Faisal Basheer and Yasuhito Nannya and Quiros, {Pedro M.} and Seishi Ogawa and Mario Cazzola and Roland Rad and Butler, {Adam P.} and Vijayabaskar, {M. S.} and Vassiliou, {George S.}",

note = "Funding Information: 1Haematological Cancer Genetics, Wellcome Sanger Institute, Hinxton, Cambridge, UK; 2Wellcome Trust–MRC Stem Cell Institute, Cambridge Biomedical Campus, University of Cambridge, Cambridge, UK; 3German Consortium for Translational Cancer Research (DKTK), Partnering Site, Munich, Germany; 4Cancer Ageing and Somatic Mutation, Wellcome Sanger Institute, Hinxton, Cambridge, UK; 5Core Software Services, Wellcome Sanger Institute, Hinxton, Cambridge, UK; 6Hospital de la Santa Creu I Sant Pau, Barcelona, Spain; 7Department of Haematology, Cambridge University Hospitals NHS Trust, Cambridge, UK; 8Department of Pathology and Tumor Biology, Graduate School of Medicine, Kyoto University, Kyoto, Japan and 9Fondazione IRCCS Policlinico San Matteo and University of Pavia, Pavia, Italy Correspondence: GEORGE VASSILIOU - [email protected] MS VIJAYABASKAR - [email protected] doi:10.3324/haematol.2019.230821 Funding: this project has received funding from the Innovative Medicines Initiative 2 Joint Undertaking under grant agreement No 116026. This Joint Undertaking receives support from the European Union´s Horizon 2020 research and innovation and EFPIA. MG is funded by Horizon 2020 (No. 116026) and Cancer Research UK (C22324/A23015). GSV is funded by a Cancer Research UK Senior Cancer Research Fellowship (C22324/A23015) and work in his laboratory is also funded by the Wellcome Trust, European Research Council, Kay Kendall Leukaemia Fund, Bloodwise, The Leukemia Lymphoma Society and the Rising Tide Foundation for Clinical Cancer Research. MSV is funded by the Wellcome Trust (WT098051). The results shown here are in part based upon data generated by the TCGA Research Network: https://www.cancer.gov/tcga. Funding Information: This project has received funding from the Innovative Medicines Initiative 2 Joint Undertaking under grant agreement No 116026. This Joint Undertaking receives support from the European Unio?s Horizon 2020 research and innovation and EFPIA. MG is funded by Horizon 2020 (No. 116026) and Cancer Research UK (C22324/A23015). GSV is funded by a Cancer Research UK Senior Cancer Research Fellowship (C22324/A23015) and work in his laboratory is also funded by the Wellcome Trust, European Research Council, Kay Kendall Leukaemia Fund, Bloodwise, The Leukemia Lymphoma Society and the Rising Tide Foundation for Clinical Cancer Research. MSV is funded by the Wellcome Trust (WT098051). The results shown here are in part based upon data generated by the TCGA Research Network: https://www.cancer.gov/tcga.",

year = "2020",

month = jun,

day = "1",

doi = "10.3324/haematol.2019.230821",

language = "English",

volume = "105",

pages = "E290--E293",

journal = "Haematologica",

issn = "0390-6078",

publisher = "Ferrata Storti Foundation",

number = "6",

}

TY - JOUR

T1 - RNAmut

T2 - Robust identification of somatic mutations in acute myeloid leukemia using RNA-sequencing

AU - Gu, Muxin

AU - Zwiebel, Maximillian

AU - Ong, Swee Hoe

AU - Boughton, Nick

AU - Nomdedeu, Josep

AU - Basheer, Faisal

AU - Nannya, Yasuhito

AU - Quiros, Pedro M.

AU - Ogawa, Seishi

AU - Cazzola, Mario

AU - Rad, Roland

AU - Butler, Adam P.

AU - Vijayabaskar, M. S.

AU - Vassiliou, George S.

N1 - Funding Information: 1Haematological Cancer Genetics, Wellcome Sanger Institute, Hinxton, Cambridge, UK; 2Wellcome Trust–MRC Stem Cell Institute, Cambridge Biomedical Campus, University of Cambridge, Cambridge, UK; 3German Consortium for Translational Cancer Research (DKTK), Partnering Site, Munich, Germany; 4Cancer Ageing and Somatic Mutation, Wellcome Sanger Institute, Hinxton, Cambridge, UK; 5Core Software Services, Wellcome Sanger Institute, Hinxton, Cambridge, UK; 6Hospital de la Santa Creu I Sant Pau, Barcelona, Spain; 7Department of Haematology, Cambridge University Hospitals NHS Trust, Cambridge, UK; 8Department of Pathology and Tumor Biology, Graduate School of Medicine, Kyoto University, Kyoto, Japan and 9Fondazione IRCCS Policlinico San Matteo and University of Pavia, Pavia, Italy Correspondence: GEORGE VASSILIOU - [email protected] MS VIJAYABASKAR - [email protected] doi:10.3324/haematol.2019.230821 Funding: this project has received funding from the Innovative Medicines Initiative 2 Joint Undertaking under grant agreement No 116026. This Joint Undertaking receives support from the European Union´s Horizon 2020 research and innovation and EFPIA. MG is funded by Horizon 2020 (No. 116026) and Cancer Research UK (C22324/A23015). GSV is funded by a Cancer Research UK Senior Cancer Research Fellowship (C22324/A23015) and work in his laboratory is also funded by the Wellcome Trust, European Research Council, Kay Kendall Leukaemia Fund, Bloodwise, The Leukemia Lymphoma Society and the Rising Tide Foundation for Clinical Cancer Research. MSV is funded by the Wellcome Trust (WT098051). The results shown here are in part based upon data generated by the TCGA Research Network: https://www.cancer.gov/tcga. Funding Information: This project has received funding from the Innovative Medicines Initiative 2 Joint Undertaking under grant agreement No 116026. This Joint Undertaking receives support from the European Unio?s Horizon 2020 research and innovation and EFPIA. MG is funded by Horizon 2020 (No. 116026) and Cancer Research UK (C22324/A23015). GSV is funded by a Cancer Research UK Senior Cancer Research Fellowship (C22324/A23015) and work in his laboratory is also funded by the Wellcome Trust, European Research Council, Kay Kendall Leukaemia Fund, Bloodwise, The Leukemia Lymphoma Society and the Rising Tide Foundation for Clinical Cancer Research. MSV is funded by the Wellcome Trust (WT098051). The results shown here are in part based upon data generated by the TCGA Research Network: https://www.cancer.gov/tcga.

PY - 2020/6/1

Y1 - 2020/6/1

UR - http://www.scopus.com/inward/record.url?scp=85085713932&partnerID=8YFLogxK

U2 - 10.3324/haematol.2019.230821

DO - 10.3324/haematol.2019.230821

M3 - Letter

C2 - 31649132

AN - SCOPUS:85085713932

SN - 0390-6078

VL - 105

SP - E290-E293

JO - Haematologica

JF - Haematologica

IS - 6

ER -

RNAmut: Robust identification of somatic mutations in acute myeloid leukemia using RNA-sequencing

Access to Document

Other files and links

Cite this